Posttreatment changes with rosuvastatin ( 40 mg/d ) in plasma ceramides were inversely associated with VLDL apoB-100 FCR ( r = -0.62 , P = .03 ) independent of changes in plasma triglycerides , cholesterol , and low-density lipoprotein-cholesterol .